- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CP-690,550
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • Cincinnati, Ohio • Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 961–984
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anaplastic Astrocytoma, IDH-Wildtype, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, IDH-Wildtype, Glioblastoma, Oligoastrocytoma, Oligodendroglioma, WHO Grade II Glioma, WHO Grade III Glioma
- Interventions
- Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
- Other · Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
- Interventions
- SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo
- Drug
- Lead sponsor
- Sound Pharmaceuticals, Incorporated
- Industry
- Eligibility
- 19 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Non-Alcoholic Steatohepatitis(NASH)
- Interventions
- Active treatment, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Anaheim, California • Durham, North Carolina
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Pembrolizumab, Placebo for pembrolizumab, Cisplatin, External Beam Radiotherapy (EBRT), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,060 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more
- Conditions
- Osteoporosis, Spinal Cord Injury
- Interventions
- Denosumab, Placebo (identical Denosumab volume of normal saline)
- Drug
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • The Bronx, New York
- Conditions
- Contraception
- Interventions
- Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Ortho Tri Cyclen Lo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 34
- States / cities
- Independence, Arizona • Phoenix, Arizona • Encinitas, California + 29 more
- Conditions
- Plaque Psoriasis
- Interventions
- CF101, Placebo
- Drug
- Lead sponsor
- Can-Fite BioPharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma, Sclc, SCLC,Extensive Stage, Lung Cancer, Lung Cancer Metastatic, Lung Cancer Stage IV
- Interventions
- BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin
- Drug
- Lead sponsor
- SystImmune Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 7
- States / cities
- Springdale, Arkansas • Glendale, California • Long Beach, California + 4 more
- Conditions
- MPS IIIA, Sanfilippo Syndrome, Sanfilippo A, Mucopolysaccharidosis III
- Interventions
- ABO-102
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
- Interventions
- ASTX727, Dacogen
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 39
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- sorafenib tosylate, tanespimycin, laboratory biomarker analysis, pharmacological study, magnetic resonance imaging
- Drug · Other · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Type 2 Diabetes
- Interventions
- euinsulinemic euglycemic glucose clamp, euinsulinemic hyperglycemic glucose clamp, Hyperinsulinemic euglycemic glucose clamp, Hyperinsulinemic hyperglycemic glucose clamp
- Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Symptomatic Neurogenic Orthostatic Hypertension, nOH
- Interventions
- Ampreloxetine <Dose A>, Ampreloxetine <Dose B>, Ampreloxetine Placebo, Moxifloxacin, Moxifloxacin Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Renal Cancer
- Interventions
- mannitol, placebo
- Drug · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Renal Function, Liver Transplant
- Interventions
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 9
- States / cities
- Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 6 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Fludarabine, Cyclophosphamide, Leukapheresis, Cytokine-induced killer cells, IL-2, ALT-803, Peripheral blood for correlative studies, Bone marrow for correlative studies
- Drug · Procedure · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Human Papilloma Virus
- Interventions
- Text-based reminder for recommended HPV vaccine or WCC, Non-specific text-based reminder (general health tip)
- Other
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 3,812 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- Interventions
- Rocatinlimab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 72
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Little Rock, Arkansas + 61 more
- Conditions
- HIV Infections, Meningitis
- Interventions
- Quadrivalent meningococcal conjugate vaccine
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 35
- States / cities
- Alhambra, California • Long Beach, California • Los Angeles, California + 25 more
- Conditions
- Endometrial Cancer
- Interventions
- Ixabepilone, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 28
- States / cities
- Mobile, Alabama • Englewood, Colorado • New Haven, Connecticut + 25 more
- Conditions
- Tympanic Membrane Perforation
- Interventions
- FGF-2, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obstetric Labour, Premature
- Interventions
- Retosiban, Atosiban, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Weeks to 20 Weeks
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 2
- States / cities
- Park Ridge, Illinois • Galveston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide
- Drug
- Lead sponsor
- Eden Biltibo
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee